Lung Cancer
Volume 55, Issue 1 , Pages 115-121 , January 2007

Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma

  • Junji Tsurutani

      Affiliations

    • Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, United States
    • Second Department of Internal Medicine, Nagasaki University School of Medicine, 17-1 Sakamoto, Nagasaki 852-8501, Japan
    • ,
  • Seth M. Steinberg

      Affiliations

    • Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, United States
    • ,
  • Marc Ballas

      Affiliations

    • Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, United States
    • ,
  • Matthew Robertson

      Affiliations

    • Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, United States
    • ,
  • Jaclyn LoPiccolo

      Affiliations

    • Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, United States
    • ,
  • Hiroshi Soda

      Affiliations

    • Second Department of Internal Medicine, Nagasaki University School of Medicine, 17-1 Sakamoto, Nagasaki 852-8501, Japan
    • ,
  • Shigeru Kohno

      Affiliations

    • Second Department of Internal Medicine, Nagasaki University School of Medicine, 17-1 Sakamoto, Nagasaki 852-8501, Japan
    • ,
  • Valgardur Egilsson

      Affiliations

    • Department of Pathology, National University Hospital, 101 Reykjavik, Iceland
    • ,
  • Phillip A. Dennis

      Affiliations

    • Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, United States
    • Corresponding Author InformationCorresponding author at: NCI/Navy Medical Oncology, Building 8, Room 5101, 8901 Wisconsin Ave., Bethesda, MD 20889, United States. Tel.: +1 301 496 0901; fax: +1 301 496 0047.

Received 22 June 2006 ,Revised 19 September 2006 ,Accepted 24 September 2006.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J Clin. 2005;55(1):10–30
  2. Scagliotti GV, Smit E, Bosquee L, O’Brien M, Ardizzoni A, Zatloukal P, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer. 2005;50(1):91–96
  3. West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol. 2005;16(7):1076–1080
  4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237–2246[corrected]
  5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132
  6. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158
  7. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(6):1103–1109
  8. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase b is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986–3997
  9. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003;111(1):81–90
  10. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3’-kinase/Akt pathway in vitro and in vivo. Cancer Res. 2004;64(2):446–451
  11. Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, et al. Tobacco components stimulate Akt-dependent proliferation and NF{kappa}B-dependent survival in lung cancer cells. Carcinogenesis. 2005;(24):
  12. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65(18):8423–8432
  13. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 2006;24(2):306–314
  14. Agresti A. Categorical data analysis. New York: John Wiley and Sons; 1990;p. 100–2
  15. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consierations. Cancer Chem Rep. 1966;50:163–170
  17. Cox D. Regression models and life tables. J R Stat Soc (B). 1972;34:187–202
  18. Matthews DE, Farewell VT. Using and understanding medical statistics. Karger: Basel; 1996;
  19. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69(6):979–985
  20. Travis WDCT, Corin B, Shimosato Y, Brambilla E, Sobin LH. World health organization: histological typing of lung and pleural tumors. Berlin: Springer; 1999;
  21. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455–7464
  22. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96(15):1133–1141
  23. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61(16):6105–6111
  24. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001;5(Suppl. 16):125–141
  25. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4(12):3005–3010
  26. Guedj N, Couvelard A, Arcangeli G, Dubois S, Thabut G, Leseche G, et al. Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours. Histopathology. 2004;44(3):251–256
  27. Erman M, Grunenwald D, Penault-Llorca F, Grenier J, Besse B, Validire P, et al. Epidermal growth factor receptor HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer. 2005;47(3):315–323
  28. Marchetti A, Pellegrini S, Bertacca G, Buttitta F, Gaeta P, Carnicelli V, et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas correlations with clinicopathological data and K-ras mutations. J Pathol. 1998;184(3):240–246
  29. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA. 2001;98(8):4622–4627
  30. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem. 2000;275(11):8027–8031
  31. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation in esophageal cancer cells. J Biol Chem. 2000;
  32. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001;98(20):11598–11603
  33. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003;63(19):6357–6362
  34. Dumont P, Gasser B, Rouge C, Massard G, Wihlm JM. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest. 1998;113(2):391–395
  35. Lin DM, Ma Y, Zheng S, Liu XY, Zou SM, Wei WQ. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol. 2006;21(6):627–632

PII: S0169-5002(06)00527-7

doi: 10.1016/j.lungcan.2006.09.026

Lung Cancer
Volume 55, Issue 1 , Pages 115-121 , January 2007

Article Tools

* Image Usage & Resolution